Author

D. Ebner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Cell Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Approach:experimental assay· 7 Research Focus:drug response / drug discovery· 6 Research Focus:cancer & tumor microenvironment· 3 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:development & morphogenesis· 2 Assay:DNA methylation· 2

Frequent Co-Authors

S. B. Hatch· 4 shared V. Millar· 3 shared C. I. Wells· 2 shared D. H. Drewry· 2 shared E. Seraia· 2 shared A. Cerutti· 1 shared A. Cicconi· 1 shared A. D. Axtman· 1 shared

Activity by Year

2019-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCell Biology

S. B. Hatch

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models

G. Rodriguez-Berriguete, M. Ranzani, R. Prevo, R. Puliyadi, N. Machado, H. R. Bolland, V. Millar, D. Ebner, M. Boursier, A. Cerutti, A. Cicconi, A. Galbiati, D. Grande, V. Grinkevich, J. Majithiya, , G. S. Higgins

This study shows that Polθ inhibitors ART558 and ART899 radiosensitize tumor cells without affecting normal fibroblasts, suggesting potential for safe cancer radiotherapy.

bioRxiv · Sep 27, 2022Cancer Biology

Small molecule screen employing patient-derived iPS hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency

D. Kent, S. S. Ng, P. Khoshkenar, A. M. Syanda, L. Chao Zheng, M. Zieger, C. Greer, S. B. Hatch, J. M. Segal, S. J. I. Blackford, V. Chowdary, T. Ismali, D. Danovi, S. Sahdeo, D. Ebner, , S. T. Rashid

A small molecule screen in patient iPSCs with in vivo validation in mice identifies LRRK2 as a new therapeutic target for Alpha-1 Antitrypsin Deficiency.

bioRxiv · Sep 17, 2021 · PreprintCell Biology

Therapeutic targeting of SETD2-deficient cancer cells with the small-molecule compound RITA

K. A. Lopez, S. Sarkar, E. Seraia, C. Toffanin, C. Cooper, M. Challoumas, F. A. Okonjo, G. D. D. Jones, F. Buffa, D. Ebner, T. C. Humphrey

This paper identifies RITA as a compound that selectively kills SETD2-deficient cancer cells by inducing p53-mediated apoptosis and replication stress.

bioRxiv · Jul 8, 2021 · PreprintCell Biology

Optimized chemogenomic library design strategies for precision oncology

P. Athanasiadis, B. Ravikumar, N. O. Carragher, P. A. Clemons, T. Johanssen, D. Ebner, T. Aittokallio

The paper presents strategies for designing optimized chemogenomic libraries for precision oncology, focusing on cancer-related targets and biological pathways.

bioRxiv · Nov 30, 2020Cancer Biology

IGF targeting perturbs global replication through ribonucleotide reductase dysfunction

G. Rieunier, X. Wu, L. Harris, J. Mills, A. Nandakumar, L. Colling, E. Seraia, S. B. Hatch, D. Ebner, L. Folkes, U. Weyer-czernilofsky, T. Bogenrieder, A. J. Ryan, V. M. Macaulay

This study shows that IGF-1R inhibition causes replication stress by reducing RNR subunit RRM2, leading to DNA damage and synthetic lethality with ATM loss in cancer cells.

bioRxiv · Aug 11, 2020Cancer Biology

The Kinase Chemogenomic Set (KCGS): An open science resource for kinase vulnerability identification

C. I. Wells, H. Al-Ali, D. M. Andrews, C. R. M. Asquith, A. D. Axtman, M. Chung, I. Dikic, D. Ebner, J. Elkins, P. Ettmayer, C. Fischer, M. Frederiksen, N. S. Gray, S. B. Hatch, S. Knapp, , D. H. Drewry

The paper introduces the Kinase Chemogenomic Set (KCGS), a curated collection of 187 selective kinase inhibitors covering 215 human kinases, for use in cell-based screens.

bioRxiv · Dec 22, 2019Cell Biology

Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response

P. Zhang, I. Kitchen-Smith, L. Xiong, G. Stracquadanio, K. Brown, P. Richter, M. Wallace, E. Bond, N. Sahgal, S. Moore, S. Nornes, S. De Val, M. Surakhy, D. Sims, X. Wang, , G. Bond

The paper investigates interactions between germline and somatic variants in the p53 pathway to show their combined effects on cancer risk, progression, and treatment response.

bioRxiv · Nov 9, 2019Cancer Biology

TCR and inflammatory signals tune human MAIT cells to exert specific tissue repair and effector functions

T. Leng, H. Delowar Akther, C.-P. Hackstein, T. King, M. Friedrich, Z. Christoforidou, S. McCuaig, M. Neyazi, C. V. Arancibia-Carcamo, F. Powrie, Oxford IBD Investigators, E. Marchi, R. Sanchesperes, V. Millar, D. Ebner, , P. Klenerman

This study investigates how TCR and inflammatory signals shape human MAIT cell functions, revealing their roles in tissue repair and effector responses.

bioRxiv · May 14, 2019Immunology

Cyclin F-Chk1 synthetic lethality mediated by E2F1 degradation

V. D'Angiolella, H. Yang, R. Faedda, S. Hume, D. Ebner, S. B. Hatch, B. Kessler, K. Burdova, I. Vendrell, D. H. Drewry, C. I. Wells

The paper identifies synthetic lethality between Chk1 inhibition and cyclin F loss, revealing Cyclin F's role in preventing DNA replication stress via E2F1 degradation.

bioRxiv · Jan 2, 2019 · PreprintCancer Biology